Merck KGaA, Darmstadt, Germany Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations

Author's Avatar
Jun 03, 2019
Article's Main Image

Not intended for UK-based media

PR Newswire